US2020383942A1PendingUtilityA1

Alkylamido Compounds and Uses Thereof

74
Assignee: NOGRA PHARMA LTDPriority: Feb 16, 2009Filed: Jan 3, 2020Published: Dec 10, 2020
Est. expiryFeb 16, 2029(~2.6 yrs left)· nominal 20-yr term from priority
A61K 2800/78A61Q 19/02A61Q 7/00C07C 233/54C07D 307/79A61Q 19/06C07D 319/08A61K 8/42A61K 2121/00A61K 31/196C07C 235/38A61Q 5/00A61Q 19/08A61P 17/10A61Q 19/008A61Q 7/02A61K 8/44
74
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Disclosed herein are compounds that may be specific to PPAR and/or EGF receptors, and methods of making and using same.

Claims

exact text as granted — not AI-modified
1 .- 19 . (canceled) 
     
     
         20 . The compound N-acetyl-(S)-3-(4-aminophenyl)-2-methoxypropionic acid, or a pharmaceutically acceptable salt or an N-oxide thereof. 
     
     
         21 . A pharmaceutical composition comprising the compound of  claim 20 , or a pharmaceutically acceptable salt or an N-oxide thereof; and a pharmaceutically acceptable carrier. 
     
     
         22 . The compound N-acetyl-(S)-3-(4-aminophenyl)-2-methoxypropionic acid, or a pharmaceutically acceptable salt thereof. 
     
     
         23 . A pharmaceutical composition comprising the compound of  claim 22 , or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. 
     
     
         24 . The compound N-acetyl-(S)-3-(4-aminophenyl)-2-methoxypropionic acid. 
     
     
         25 . A pharmaceutical composition comprising the compound of  claim 24 ; and a pharmaceutically acceptable carrier.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.